Skip to Content

Caliway Biopharmaceuticals Co Ltd 6919

Morningstar Rating
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

6919 is trading at a 391% premium.
Price
TWD 380.34
Fair Value
TWD 681.83
Uncertainty
Extreme
1-Star Price
TWD 4,724.68
5-Star Price
TWD 22.44
Economic Moat
Vnhsc
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 6919 is a good fit for your portfolio.

Trading Information

Previous Close Price
Day Range
52-Week Range
Bid/Ask
/
Market Cap
Volume/Avg
/

Key Statistics

Price/Earnings (Normalized)
Price/Sales
594.32
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Caliway Biopharmaceuticals Co Ltd is specialized in the development of new drugs for medical aesthetic and inflammatory diseases. Its leading candidate, CBL-514, is a new drug that can trigger adipocyte apoptosis at the injection site and effectively reduce subcutaneous fat without causing tissue necrosis or prominent side effects.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Mid Growth
Total Number of Employees
41

Comparables

Valuation

Metric
6919
6535
6696
Price/Earnings (Normalized)
Price/Book Value
14.9223.413.24
Price/Sales
594.32556.03
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
6919
6535
6696
Quick Ratio
31.073.9813.67
Current Ratio
31.284.7514.10
Interest Coverage
−1,381.29−5,543.09−647.17
Quick Ratio
6919
6535
6696

Profitability

Metric
6919
6535
6696
Return on Assets (Normalized)
−20.90%−22.08%−37.22%
Return on Equity (Normalized)
−21.62%−25.48%−61.30%
Return on Invested Capital (Normalized)
−22.12%−25.35%−39.00%
Return on Assets
6919
6535
6696
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRNltgcpdwcMjzs$593.5 Bil
VRTX
Vertex Pharmaceuticals IncHrddbkcvQkyqky$113.7 Bil
REGN
Regeneron Pharmaceuticals IncZnbxsgxgkQrcrpwn$106.7 Bil
MRNA
Moderna IncSscnqxsStmj$50.8 Bil
BNTX
BioNTech SE ADRBkhmgqsnZkng$22.4 Bil
ARGX
argenx SE ADRWcdltwgktRgc$22.2 Bil
ALNY
Alnylam Pharmaceuticals IncTqzwsxwfzSllbsm$19.1 Bil
BMRN
Biomarin Pharmaceutical IncDqfxqzwwkKvzqw$14.6 Bil
INCY
Incyte CorpFcgtrpztTflpkh$12.8 Bil
RPRX
Royalty Pharma PLC Class AWxmpshdrfKtqnc$12.6 Bil

Sponsor Center